deferoxamine has been researched along with Cardiomyopathies in 59 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Deferoxamine mesylate (DFO) reduces morbidity and mortality associated with transfusional iron overload." | 7.74 | Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. ( Baladi, JF; Coates, TD; Delea, TE; Hagiwara, M; Phatak, PD; Thomas, SK, 2008) |
| "To evaluate the effects of the iron chelator deferoxamine on the functional and structural manifestations of iron-induced cardiac dysfunction, we measured cardiac power, left ventricular systolic, and diastolic function as (dP/dt)max and (dP/dt)min, respectively, and left ventricular and septal wall thickness in isolated heart preparations derived from the Mongolian gerbil model of iron overload." | 7.72 | Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy. ( Brittenham, GM; Brown, AM; Dong, WQ; Kuryshev, YA; Levy, MN; Obejero-Paz, CA; Yang, T, 2003) |
| "We examined the efficacy of long-term subcutaneous deferoxamine therapy in the prevention of iron-related cardiac disease in patients with thalassemia major who began treatment after the age of 10 years." | 7.67 | Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. ( Colan, S; Freedman, MH; Nathan, DG; Olivieri, N; Propper, R; Rose, V; Sallan, D; Wolfe, L, 1985) |
| "Deferiprone monotherapy was significantly more effective than deferoxamine over 1 year in improving asymptomatic myocardial siderosis in beta-thalassemia major." | 6.72 | Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. ( Aessopos, A; Berdoukas, V; Galanello, R; Gotsis, ED; Karagiorga, M; Ladis, V; Pennell, DJ; Piga, A; Smith, GC; Tanner, MA; Westwood, MA; Wonke, B, 2006) |
| "Deferiprone has been reported to be superior to deferoxamine for the removal of cardiac iron and improvement in left ventricular (LV) function but little is known of their relative effects on the right ventricle (RV), which is being increasingly recognised as an important prognostic factor in cardiomyopathy." | 5.37 | Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. ( Aessopos, A; Alam, MH; Alpendurada, F; Berdoukas, V; Carpenter, JP; Galanello, R; Gotsis, ED; Karagiorga, M; Ladis, V; Pennell, DJ; Piga, A; Roughton, M; Smith, GC; Tanner, MA; Westwood, MA, 2011) |
| "We enrolled nine patients with thalassemia major complicated by some degree of myocardial dysfunction." | 5.33 | Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients. ( Chang, JS; Huang, YC; Peng, CT; Wu, KH, 2006) |
| " In 18 requiring thyroxine supplementation for hypothyroidism, 10 were able to discontinue, and four reduced their thyroxine dose." | 5.14 | Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. ( Berdoukas, V; Chouliaras, G; Farmaki, K; Pappa, C; Tzoumari, I, 2010) |
| "In patients with severe myocardial siderosis and impaired LV function, combined chelation therapy with subcutaneous deferoxamine and oral deferiprone reduces myocardial iron and improves cardiac function." | 5.13 | Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. ( Agus, A; Dessi, C; Galanello, R; Nair, SV; Pennell, DJ; Pibiri, M; Smith, GC; Tanner, MA; Walker, JM; Westwood, MA, 2008) |
| "The iron chelators deferoxamine (DFO) and deferiprone (L1) have demonstrated their ability to normalize cardiac function in patients with iron overload-induced cardiac disease." | 4.84 | Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience. ( Peng, CT; Tsai, CH; Wu, KH, 2008) |
| "Therapy with either deferiprone (DFP) or deferoxamine (DFO) is inadequate in achieving negative iron balance in many patients with thalassemia." | 4.82 | Combined therapy with deferoxamine and deferiprone. ( Kattamis, A, 2005) |
| "Deferoxamine mesylate (DFO) reduces morbidity and mortality associated with transfusional iron overload." | 3.74 | Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. ( Baladi, JF; Coates, TD; Delea, TE; Hagiwara, M; Phatak, PD; Thomas, SK, 2008) |
| " We used cardiovascular magnetic resonance (CMR) to assess the prevalence of myocardial iron overload and ventricular dysfunction in a large cohort of TM patients maintained on conventional chelation treatment with deferoxamine." | 3.73 | Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. ( Anderson, LJ; Dessi, C; Galanello, R; Nair, SV; Pennell, DJ; Smith, GC; Tanner, MA; Walker, JM; Westwood, MA, 2006) |
| "The incidence of cardiomyopathy was monitored in a 6-year follow-up study involving 56 transfused thalassemia patients treated with deferoxamine (DFO), deferiprone (L1) or their combination." | 3.73 | Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*. ( Economides, C; Eracleous, E; Kolnagou, A; Kontoghiorghes, GJ, 2006) |
| "We investigated the time course of electrocardiographic (ECG) changes in the Mongolian gerbil model of iron overload and the effects of the iron chelator deferoxamine (DFO) on these changes." | 3.72 | Deferoxamine promotes survival and prevents electrocardiographic abnormalities in the gerbil model of iron-overload cardiomyopathy. ( Brittenham, GM; Brown, AM; Dong, WQ; Kuryshev, YA; Levy, MN; Obejero-Paz, CA; Yang, T, 2003) |
| "To evaluate the effects of the iron chelator deferoxamine on the functional and structural manifestations of iron-induced cardiac dysfunction, we measured cardiac power, left ventricular systolic, and diastolic function as (dP/dt)max and (dP/dt)min, respectively, and left ventricular and septal wall thickness in isolated heart preparations derived from the Mongolian gerbil model of iron overload." | 3.72 | Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy. ( Brittenham, GM; Brown, AM; Dong, WQ; Kuryshev, YA; Levy, MN; Obejero-Paz, CA; Yang, T, 2003) |
| "We examined the efficacy of long-term subcutaneous deferoxamine therapy in the prevention of iron-related cardiac disease in patients with thalassemia major who began treatment after the age of 10 years." | 3.67 | Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. ( Colan, S; Freedman, MH; Nathan, DG; Olivieri, N; Propper, R; Rose, V; Sallan, D; Wolfe, L, 1985) |
| "Deferiprone monotherapy was significantly more effective than deferoxamine over 1 year in improving asymptomatic myocardial siderosis in beta-thalassemia major." | 2.72 | Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. ( Aessopos, A; Berdoukas, V; Galanello, R; Gotsis, ED; Karagiorga, M; Ladis, V; Pennell, DJ; Piga, A; Smith, GC; Tanner, MA; Westwood, MA; Wonke, B, 2006) |
| "Thalassemia is anemia of variable severity, arising from mutations of genes encoding the hemoglobin alpha and beta chains." | 2.44 | Mechanisms of and obstacles to iron cardiomyopathy in thalassemia. ( Chang, JS; Lin, HS; Peng, CT; Tsai, CH; Wu, KH, 2008) |
| "Deferasirox monotherapy was less effective than deferiprone in improving myocardial siderosis and biventricular function and less effective than desferrioxamine in improving the LVEF." | 1.48 | MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine. ( Allò, M; Cuccia, L; D'Ascola, DG; Gamberini, MR; Lisi, R; Mangione, M; Meloni, A; Pepe, A; Pistoia, L; Positano, V; Restaino, G; Ricchi, P; Righi, R; Rosso, R; Spasiano, A, 2018) |
| "Iron chelators are used to treat iron overload cardiomyopathy patients." | 1.43 | Combined Iron Chelator and Antioxidant Exerted Greater Efficacy on Cardioprotection Than Monotherapy in Iron-Overloaded Rats. ( Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Khamseekaew, J; Kumfu, S; Srichairatanakool, S; Sripetchwandee, J; Wongjaikam, S, 2016) |
| "Deferiprone has been reported to be superior to deferoxamine for the removal of cardiac iron and improvement in left ventricular (LV) function but little is known of their relative effects on the right ventricle (RV), which is being increasingly recognised as an important prognostic factor in cardiomyopathy." | 1.37 | Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. ( Aessopos, A; Alam, MH; Alpendurada, F; Berdoukas, V; Carpenter, JP; Galanello, R; Gotsis, ED; Karagiorga, M; Ladis, V; Pennell, DJ; Piga, A; Roughton, M; Smith, GC; Tanner, MA; Westwood, MA, 2011) |
| "Myocardial iron overload is the leading cause of death in patients with beta-thalassemia major." | 1.36 | Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone. ( Bina, P; Carta, MP; Cianciulli, P; Farci, P; Galanello, R; Grady, RW; Lai, ME; Maggio, A; Pepe, A; Sau, F; Vacquer, S, 2010) |
| "We enrolled nine patients with thalassemia major complicated by some degree of myocardial dysfunction." | 1.33 | Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients. ( Chang, JS; Huang, YC; Peng, CT; Wu, KH, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (15.25) | 18.7374 |
| 1990's | 8 (13.56) | 18.2507 |
| 2000's | 30 (50.85) | 29.6817 |
| 2010's | 9 (15.25) | 24.3611 |
| 2020's | 3 (5.08) | 2.80 |
| Authors | Studies |
|---|---|
| Kumfu, S | 2 |
| Sripetchwandee, J | 2 |
| Thonusin, C | 1 |
| Sumneang, N | 1 |
| Maneechote, C | 1 |
| Arunsak, B | 1 |
| Chunchai, T | 1 |
| Oo, TT | 1 |
| Kongkaew, A | 1 |
| Chattipakorn, SC | 2 |
| Chattipakorn, N | 2 |
| Pepe, A | 4 |
| Meloni, A | 3 |
| Filosa, A | 2 |
| Pistoia, L | 2 |
| Borsellino, Z | 1 |
| D'Ascola, DG | 2 |
| Lisi, R | 2 |
| Putti, MC | 2 |
| Allò, M | 2 |
| Gamberini, MR | 2 |
| Quarta, A | 1 |
| Fidone, C | 1 |
| Casini, T | 1 |
| Restaino, G | 2 |
| Midiri, M | 2 |
| Mangione, M | 2 |
| Positano, V | 3 |
| Casale, M | 1 |
| Pinto, VM | 1 |
| Forni, GL | 1 |
| Lee, JA | 1 |
| Tchantchaleishvili, V | 1 |
| Vidula, H | 1 |
| Cuccia, L | 2 |
| Rosso, R | 1 |
| Spasiano, A | 1 |
| Righi, R | 1 |
| Ricchi, P | 2 |
| Gammella, E | 1 |
| Recalcati, S | 1 |
| Rybinska, I | 1 |
| Buratti, P | 1 |
| Cairo, G | 1 |
| Wongjaikam, S | 1 |
| Khamseekaew, J | 1 |
| Srichairatanakool, S | 1 |
| Fucharoen, S | 1 |
| Tauchenová, L | 1 |
| Křížová, B | 1 |
| Kubánek, M | 1 |
| Fraňková, S | 1 |
| Melenovský, V | 1 |
| Tintěra, J | 1 |
| Kautznerová, D | 1 |
| Malušková, J | 1 |
| Jirsa, M | 1 |
| Kautzner, J | 1 |
| Peng, CT | 5 |
| Chang, JS | 3 |
| Wu, KH | 5 |
| Tsai, CH | 2 |
| Lin, HS | 1 |
| Wang, LY | 1 |
| Chiou, SS | 1 |
| Hsiao, CC | 1 |
| Wang, SC | 1 |
| Hung, GY | 1 |
| Farmaki, K | 1 |
| Tzoumari, I | 1 |
| Pappa, C | 1 |
| Chouliaras, G | 1 |
| Berdoukas, V | 4 |
| Sugishita, K | 1 |
| Asakawa, M | 1 |
| Usui, S | 1 |
| Takahashi, T | 1 |
| Lai, ME | 1 |
| Grady, RW | 1 |
| Vacquer, S | 1 |
| Carta, MP | 1 |
| Bina, P | 1 |
| Sau, F | 1 |
| Cianciulli, P | 2 |
| Maggio, A | 1 |
| Galanello, R | 6 |
| Farci, P | 1 |
| Smith, GC | 4 |
| Alpendurada, F | 1 |
| Carpenter, JP | 1 |
| Alam, MH | 1 |
| Karagiorga, M | 2 |
| Ladis, V | 2 |
| Piga, A | 4 |
| Aessopos, A | 2 |
| Gotsis, ED | 2 |
| Tanner, MA | 4 |
| Westwood, MA | 6 |
| Roughton, M | 1 |
| Pennell, DJ | 9 |
| Rossi, G | 1 |
| D'Ascola, GD | 1 |
| Santodirocco, M | 1 |
| Caruso, V | 1 |
| Romeo, MA | 1 |
| Pitrolo, L | 1 |
| Peluso, A | 1 |
| Campisi, S | 1 |
| Missere, M | 1 |
| Gulino, L | 1 |
| Lombardi, M | 1 |
| Brittenham, GM | 3 |
| Nathan, DG | 2 |
| Olivieri, NF | 1 |
| Pippard, MJ | 1 |
| Weatherall, DJ | 1 |
| Hoffband, AV | 1 |
| Vogel, M | 1 |
| Anderson, LJ | 5 |
| Holden, S | 2 |
| Deanfield, JE | 1 |
| Walker, JM | 5 |
| Obejero-Paz, CA | 2 |
| Yang, T | 2 |
| Dong, WQ | 2 |
| Levy, MN | 2 |
| Kuryshev, YA | 2 |
| Brown, AM | 2 |
| West, M | 1 |
| Malik, GA | 1 |
| Pollock, JC | 1 |
| Westwood, M | 1 |
| Hershko, C | 3 |
| Cappellini, MD | 1 |
| Tognoni, G | 1 |
| Masera, G | 1 |
| Davis, B | 1 |
| Prescott, E | 2 |
| Wonke, B | 3 |
| Porter, JB | 1 |
| Link, G | 2 |
| Konijn, AM | 1 |
| Cabantchik, ZI | 1 |
| Kattamis, A | 1 |
| Roggero, S | 1 |
| Vinciguerra, T | 1 |
| Sacchetti, L | 1 |
| Gallo, V | 1 |
| Longo, F | 1 |
| Dessi, C | 2 |
| Nair, SV | 2 |
| Kolnagou, A | 3 |
| Economides, C | 1 |
| Eracleous, E | 1 |
| Kontoghiorghes, GJ | 3 |
| Huang, YC | 1 |
| Chang, JG | 1 |
| Ho, YJ | 1 |
| Wu, SF | 1 |
| Delea, TE | 1 |
| Hagiwara, M | 1 |
| Thomas, SK | 1 |
| Baladi, JF | 1 |
| Phatak, PD | 1 |
| Coates, TD | 1 |
| Modell, B | 1 |
| Kidson-Gerber, GL | 1 |
| Francis, S | 1 |
| Lindeman, R | 1 |
| Michaelides, Y | 1 |
| Kontos, C | 1 |
| Kyriacou, K | 1 |
| Agus, A | 1 |
| Pibiri, M | 1 |
| Kondur, AK | 1 |
| Li, T | 1 |
| Vaitkevicius, P | 1 |
| Afonso, L | 1 |
| Ley, TJ | 1 |
| Griffith, P | 1 |
| Nienhuis, AW | 1 |
| Pisano, GF | 1 |
| Binaghi, F | 1 |
| Putzu, ML | 1 |
| Bragotti, R | 1 |
| Manconi, E | 1 |
| Urgu, G | 1 |
| Pitzus, F | 1 |
| Herman, EH | 1 |
| Zhang, J | 1 |
| Ferrans, VJ | 1 |
| Richardson, ME | 1 |
| Matthews, RN | 1 |
| Alison, JF | 1 |
| Menahem, S | 1 |
| Mitvalsky, J | 1 |
| Byrt, E | 1 |
| Harper, RW | 1 |
| Swartz, RD | 1 |
| Legault, DJ | 1 |
| Madani, TA | 1 |
| Bormanis, J | 1 |
| Cabantchik, I | 1 |
| Simon, M | 1 |
| Bourel, M | 1 |
| Perrimond, H | 1 |
| Chagnon, C | 1 |
| Moulanier, I | 1 |
| Michel, G | 1 |
| Guidicelli, H | 1 |
| Bernard, PJ | 1 |
| Cecchetti, G | 1 |
| Binda, A | 1 |
| Piperno, A | 1 |
| Nador, F | 1 |
| Fargion, S | 1 |
| Fiorelli, G | 1 |
| Scieszka, J | 1 |
| Kalina, Z | 1 |
| Knap, J | 1 |
| Farber, NE | 1 |
| Vercellotti, GM | 1 |
| Jacob, HS | 1 |
| Pieper, GM | 1 |
| Gross, GJ | 1 |
| van der Kraaij, AM | 1 |
| Mostert, LJ | 1 |
| van Eijk, HG | 1 |
| Koster, JF | 1 |
| Scheer, RL | 1 |
| Wolfe, L | 1 |
| Olivieri, N | 1 |
| Sallan, D | 1 |
| Colan, S | 1 |
| Rose, V | 1 |
| Propper, R | 1 |
| Freedman, MH | 1 |
| Piomelli, S | 1 |
| Danoff, SJ | 1 |
| Becker, MH | 1 |
| Lipera, MJ | 1 |
| Travis, SF | 1 |
| Moretti, G | 1 |
| Staeffen, J | 1 |
| Galley, P | 1 |
| Mulet, M | 1 |
| Descamps, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Placebo Controlled, Double Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance[NCT00103753] | Phase 4 | 65 participants | Interventional | 2004-05-31 | Active, not recruiting | ||
| The Effect of Treatment With the Oral Iron Chelator Deferiprone on the Oxidative Stress of Blood Cells and on Iron Overload Status in Transfusion Dependent, Iron-overloaded Patients With Low Risk Myelodysplastic Syndrome[NCT02477631] | Phase 2 | 19 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| A Pilot Study of 5-Azacytidine and Oral Sodium Phenylbutyrate in Severe Thalassemia[NCT00005934] | Phase 2 | 24 participants | Interventional | 2000-06-30 | Completed | ||
| Effect of Hydroxyurea on the Level of Ineffective Erythropoiesis, Transfusion Requirement, and Fetal Hemoglobin Synthesis in Patients With Beta-Thalassemia-Intermedia[NCT00001958] | Phase 2 | 100 participants | Interventional | 1999-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for deferoxamine and Cardiomyopathies
| Article | Year |
|---|---|
Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series.
Topics: Adult; beta-Thalassemia; Blood Transfusion; Cardiomyopathies; Chelation Therapy; Deferoxamine; Drug | 2020 |
Iron-induced damage in cardiomyopathy: oxidative-dependent and independent mechanisms.
Topics: Animals; Cardiomyopathies; Deferoxamine; Disease Models, Animal; Humans; Iron; Iron Overload; Iron-R | 2015 |
Mechanisms of and obstacles to iron cardiomyopathy in thalassemia.
Topics: Blood Pressure; Cardiomyopathies; Deferoxamine; Electrocardiography; Heart; Heart Failure; Humans; I | 2008 |
Purging iron from the heart.
Topics: Cardiomyopathies; Cardiotonic Agents; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron | 2004 |
Objectives and mechanism of iron chelation therapy.
Topics: Animals; Benzoates; Cardiomyopathies; Cells, Cultured; Chelation Therapy; Clinical Trials as Topic; | 2005 |
Combined therapy with deferoxamine and deferiprone.
Topics: Agranulocytosis; Biological Transport; Cardiomyopathies; Chelation Therapy; Clinical Trials as Topic | 2005 |
Deferiprone: New insight.
Topics: Agranulocytosis; Cardiomyopathies; Clinical Trials as Topic; Deferiprone; Deferoxamine; Follow-Up St | 2005 |
T2* magnetic resonance and myocardial iron in thalassemia.
Topics: Adult; Calibration; Cardiomyopathies; Chelation Therapy; Child; Cohort Studies; Combined Modality Th | 2005 |
Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience.
Topics: Cardiomyopathies; Chelation Therapy; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelat | 2008 |
Quantification of myocardial iron overload by cardiovascular magnetic resonance imaging T2* and review of the literature.
Topics: Animals; Cardiomyopathies; Deferoxamine; Early Diagnosis; Female; Heart Failure; Hemosiderosis; Huma | 2009 |
Transfusion haemosiderosis and chelation therapy.
Topics: Adolescent; Adult; Ascorbic Acid; Blood Transfusion; Cardiomyopathies; Deferoxamine; Dose-Response R | 1982 |
Pathophysiology of iron overload.
Topics: Animals; Cardiomyopathies; Deferoxamine; Free Radicals; Humans; Iron; Siderosis; Thalassemia; Transf | 1998 |
[Idiopathic haemochromatosis. I. Clinical, biological and therapeutic aspects (author's transl)].
Topics: Bloodletting; Bone Diseases; Cardiomyopathies; Deferoxamine; Diabetes Mellitus; Female; Ferritins; H | 1979 |
[Hemochromatosis of the heart].
Topics: Cardiomyopathies; Deferoxamine; Hemochromatosis; Humans; Iron; Myocardium | 1990 |
4 trials available for deferoxamine and Cardiomyopathies
| Article | Year |
|---|---|
Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Glucose; Cardiomyopathies; Child; Deferiprone; Deferoxami | 2010 |
Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.
Topics: Adult; beta-Thalassemia; Cardiomyopathies; Deferiprone; Deferoxamine; Female; Humans; Iron; Iron Che | 2006 |
Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
Topics: Administration, Oral; beta-Thalassemia; Cardiomyopathies; Chelation Therapy; Clinical Protocols; Com | 2006 |
Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.
Topics: Administration, Oral; Adult; beta-Thalassemia; Cardiomyopathies; Deferiprone; Deferoxamine; Drug The | 2008 |
41 other studies available for deferoxamine and Cardiomyopathies
| Article | Year |
|---|---|
Ferroptosis inhibitor improves cardiac function more effectively than inhibitors of apoptosis and necroptosis through cardiac mitochondrial protection in rats with iron-overloaded cardiomyopathy.
Topics: Animals; Apoptosis; Cardiomyopathies; Deferoxamine; Ferroptosis; Humans; Iron; Iron Overload; Male; | 2023 |
Prospective CMR Survey in Children With Thalassemia Major: Insights From a National Network.
Topics: Adolescent; Age Factors; beta-Thalassemia; Cardiomyopathies; Child; Deferiprone; Deferoxamine; Femal | 2020 |
Cardiac Hemochromatosis Treated With Prolonged Extracorporeal Membrane Oxygenation Support and Chelation Therapy.
Topics: Adult; Cardiomyopathies; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Extracorporeal M | 2018 |
MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine.
Topics: Adult; beta-Thalassemia; Cardiomyopathies; Deferasirox; Deferiprone; Deferoxamine; Drug Substitution | 2018 |
Combined Iron Chelator and Antioxidant Exerted Greater Efficacy on Cardioprotection Than Monotherapy in Iron-Overloaded Rats.
Topics: Acetylcysteine; Animals; Benzoates; Cardiomyopathies; Cardiotonic Agents; Deferasirox; Deferiprone; | 2016 |
Successful Treatment of Iron-Overload Cardiomyopathy in Hereditary Hemochromatosis With Deferoxamine and Deferiprone.
Topics: Cardiomyopathies; Deferiprone; Deferoxamine; Ferritins; Heart Failure; Hemochromatosis; Hemochromato | 2016 |
Update on thalassemia treatment in Taiwan, including bone marrow transplantation, chelation therapy, and cardiomyopathy treatment effects.
Topics: Benzoates; beta-Thalassemia; Blood Transfusion; Bone Marrow Transplantation; Cardiomyopathies; Chela | 2009 |
A case of iron overload cardiomyopathy: beneficial effects of iron chelating agent and calcium channel blocker on left ventricular dysfunction.
Topics: Aged, 80 and over; Calcium Channel Blockers; Cardiomyopathies; Deferoxamine; Ferritins; Humans; Iron | 2009 |
Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
Topics: Adult; beta-Thalassemia; Cardiomyopathies; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therap | 2010 |
Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload.
Topics: Adult; Analysis of Variance; beta-Thalassemia; Cardiomyopathies; Deferiprone; Deferoxamine; Female; | 2011 |
Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy.
Topics: Adult; Analysis of Variance; beta-Thalassemia; Cardiomyopathies; Chi-Square Distribution; Deferipron | 2013 |
Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
Topics: beta-Thalassemia; Cardiomyopathies; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Pyrido | 2003 |
A sensitive test for early myocardial iron loading.
Topics: beta-Thalassemia; Cardiomyopathies; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Magn | 2003 |
Tissue Doppler echocardiography in patients with thalassaemia detects early myocardial dysfunction related to myocardial iron overload.
Topics: Adolescent; Adult; beta-Thalassemia; Cardiomyopathies; Chelating Agents; Deferoxamine; Echocardiogra | 2003 |
Deferoxamine promotes survival and prevents electrocardiographic abnormalities in the gerbil model of iron-overload cardiomyopathy.
Topics: Animals; Cardiomyopathies; Deferoxamine; Disease Models, Animal; Dose-Response Relationship, Drug; E | 2003 |
Surgical resection of multiple right atrial masses in a child with beta thalassaemia and receiving desferioxamine.
Topics: Adolescent; beta-Thalassemia; Calcinosis; Cardiac Catheterization; Cardiomyopathies; Catheters, Indw | 2003 |
Treatment of cardiac iron overload in thalassemia major.
Topics: beta-Thalassemia; Cardiomyopathies; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart Dise | 2003 |
Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy.
Topics: Animals; Cardiomegaly; Cardiomyopathies; Deferoxamine; Female; Gerbillinae; Heart Failure; Iron; Iro | 2003 |
Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance.
Topics: Adult; Cardiomyopathies; Case-Control Studies; Deferoxamine; Female; Humans; Infusions, Intravenous; | 2004 |
Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine.
Topics: beta-Thalassemia; Cardiomyopathies; Child; Deferoxamine; Ferritins; Heart; Humans; Iron; Iron Overlo | 2006 |
Myocardial iron loading in patients with thalassemia major on deferoxamine chelation.
Topics: beta-Thalassemia; Cardiomyopathies; Chi-Square Distribution; Deferoxamine; Female; Ferritins; Humans | 2006 |
Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
Topics: Administration, Oral; Adult; Arrhythmias, Cardiac; Cardiomyopathies; Chelation Therapy; Combined Mod | 2006 |
Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients.
Topics: Adolescent; Adult; beta-Thalassemia; Cardiomegaly; Cardiomyopathies; Chelation Therapy; Cohort Studi | 2006 |
Glutathione S-transferase M1 gene polymorphisms are associated with cardiac iron deposition in patients with beta-thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Cardiomyopathies; Chelation Therapy; Child; Combined Modality T | 2006 |
Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Cardiomyopathies; Chelation Therapy; Child; Child, Preschool | 2008 |
Transfusion-dependent thalassaemia: a new era.
Topics: Benzoates; Cardiomyopathies; Deferasirox; Deferiprone; Deferoxamine; Drug Prescriptions; Erythrocyte | 2008 |
Management and clinical outcomes of transfusion-dependent thalassaemia major in an Australian tertiary referral clinic.
Topics: Adult; Age Factors; Australia; Cardiomyopathies; Deferiprone; Deferoxamine; Diabetes Mellitus; Drug | 2008 |
Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
Topics: Cardiomyopathies; Chelation Therapy; Deferiprone; Deferoxamine; Female; Ferritins; Humans; Iron; Iro | 2008 |
[Monitoring of the harmful effects of iron on the hearts of patients with beta-thalassemia major, using non-invasive cardiological technics].
Topics: Adolescent; Adult; Cardiomyopathies; Child; Child, Preschool; Deferoxamine; Echocardiography; Electr | 1981 |
Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Body Weight; Cardiomyopathies; Deferoxamine; Doxorubicin; Heart Rate; Injec | 1994 |
Prevention of heart disease by subcutaneous desferrioxamine in patients with thalassaemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Cardiomyopathies; Child; Deferoxamine; Electrocardiography; Fem | 1993 |
Long-term intraperitoneal deferoxamine for hemochromatosis.
Topics: Adult; Cardiomyopathies; Deferoxamine; Female; Hemochromatosis; Humans; Injections, Intraperitoneal; | 1996 |
Reversible severe hereditary hemochromatotic cardiomyopathy.
Topics: Adult; Cardiomyopathies; Deferoxamine; Hemochromatosis; Humans; Male; Phlebotomy; Severity of Illnes | 1997 |
[The value of nuclear magnetic resonance in the study of iron overload in thalassemia patients].
Topics: Adolescent; Adult; Alanine Transaminase; Cardiomyopathies; Child; Deferoxamine; Ferritins; Hemosider | 1991 |
Cardiac alterations in 36 consecutive patients with idiopathic haemochromatosis: polygraphic and echocardiographic evaluation.
Topics: Adult; Bloodletting; Cardiomyopathies; Deferoxamine; Echocardiography; Echocardiography, Doppler; El | 1991 |
Evidence for a role of iron-catalyzed oxidants in functional and metabolic stunning in the canine heart.
Topics: Animals; Cardiomyopathies; Coronary Circulation; Deferoxamine; Dogs; Energy Metabolism; Female; Free | 1988 |
Iron-load increases the susceptibility of rat hearts to oxygen reperfusion damage. Protection by the antioxidant (+)-cyanidanol-3 and deferoxamine.
Topics: Animals; Antioxidants; Cardiomyopathies; Catechin; Coronary Circulation; Deferoxamine; Disease Susce | 1988 |
Myocardial mucormycosis with emboli in a hemodialysis patient.
Topics: Cardiomyopathies; Deferoxamine; Humans; Mucormycosis; Renal Dialysis | 1987 |
Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.
Topics: Adolescent; Arrhythmias, Cardiac; Aspartate Aminotransferases; Cardiomyopathies; Child; Deferoxamine | 1985 |
Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.
Topics: Adolescent; Arrhythmias, Cardiac; Aspartate Aminotransferases; Cardiomyopathies; Child; Deferoxamine | 1985 |
Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.
Topics: Adolescent; Arrhythmias, Cardiac; Aspartate Aminotransferases; Cardiomyopathies; Child; Deferoxamine | 1985 |
Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.
Topics: Adolescent; Arrhythmias, Cardiac; Aspartate Aminotransferases; Cardiomyopathies; Child; Deferoxamine | 1985 |
Prevention of bone malformations and cardiomegaly in Cooley's anemia by early hypertransfusion regimen.
Topics: Blood Transfusion; Bone Diseases, Developmental; Cardiomyopathies; Child; Child, Preschool; Deferoxa | 1969 |
[Clinically isolated cardiac hemochromatosis treated with success by desferrioxamine].
Topics: Adult; Cardiomyopathies; Deferoxamine; Hemochromatosis; Humans; In Vitro Techniques; Male | 1965 |